Incubator Addition: Arix CIO On Why Fund Added VelosBio To Portfolio

Incubator fund Arix Bioscience has expanded its start-up portfolio to 15 by co-leading a series A financing for - and taking an equity stake in – antibody-drug conjugate specialist VelosBio. CIO Joe Anderson explains why.

Growth
VelosBio Now Readying For Launch Trials In cancer cell-targeting ADCs • Source: Shutterstock

Arix Bioscience PLC has added a developer of novel antibody-drug conjugates to its oncology portfolio by co-leading a $50m Series A investment round for privately-held VelosBio Inc and taking an 11.2% stake in the US-based next-generation oncology group.

Joe Anderson, Arix's chief investment officer, noted in an interview that the addition of ADC discovery and development in the fund's portfolio adds a valuable dimension to the existing list of oncology therapy-focused companies there which already comprise the CAR-T field, tri-specific T-cell engagers, viral nanoparticles activated

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business